Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 664-674
DOI: 10.1200/jco.22.01000 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von Eric Bouffet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Melanoma, Glioma, Skin Neoplasms. Die Arbeit wurde bisher 187-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs). Here, we describe a phase I/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600–mutant LGG; other cohorts will be reported elsewhere. METHODS This is a four-part, phase I/II study (ClinicalTrials.gov identifier: NCT02124772 ) in patients age < 18 years with relapsed/refractory malignancies: trametinib monotherapy dose finding (part A) and disease-specific expansion (part B), and dabrafenib + trametinib dose finding (part C) and disease-specific expansion (part D). The primary objective assessed in all patients in parts A and C was to determine pediatric dosing on the basis of steady-state pharmacokinetics. Disease-specific efficacy and safety (across parts A-D) were secondary objectives. RESULTS Overall, 139 patients received trametinib (n = 91) or dabrafenib + trametinib (n = 48). Trametinib dose-limiting toxicities in > 1 patient (part A) included mucosal inflammation (n = 3) and hyponatremia (n = 2). There were no dose-limiting toxicities with combination therapy (part C). The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg/kg once daily for patients age < 6 years and 0.025 mg/kg once daily for patients age ≥ 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy. In 49 patients with BRAF V600–mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36). Adverse event–related treatment discontinuations were more common with monotherapy (54% v 22%). CONCLUSION The trial design provided efficient evaluation of pediatric dosing, safety, and efficacy of single-agent and combination targeted therapy. Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600–mutant LGG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada.
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, INSERM U1015, Université Paris-Saclay, Villejuif, France.
- University of Minnesota Masonic Children's Hospital, Minneapolis, MN.
- Institut Curie, PSL Research University, Oncology Center SIREDO, Paris, France.
- Great Ormond Street Hospital for Children, London, United Kingdom.
- Novartis Farmaceutica S.A., Barcelona, Spain.
ORCID-Profile: Eric Bouffet, Birgit Geoerger, James A Whitlock, Darren Hargrave, Mark Russo, Elizabeth Fox
Zitieren
APA
Bouffet, E., Geoerger, B., Moertel, C., Whitlock, J. A., Aerts, I., Hargrave, D., Osterloh, L., Tan, E., Choi, J., Russo, M., & Fox, E. (2023). Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma. Journal of Clinical Oncology, 41(3), 664-674. https://doi.org/10.1200/jco.22.01000
Vancouver
Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, et al. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma. Journal of Clinical Oncology. 2023;41(3):664-674. doi:10.1200/jco.22.01000
BibTeX
@article{Bouffet2023,
author = {Bouffet, Eric and Geoerger, Birgit and Moertel, Christopher and Whitlock, James A and Aerts, Isabelle and Hargrave, Darren and Osterloh, Lisa and Tan, Eugene and Choi, Jeea and Russo, Mark and Fox, Elizabeth},
title = {Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {3},
pages = {664--674},
doi = {10.1200/jco.22.01000}
}
EUVIMED